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Human Papilloma Virus (HPV) are a heterogeneous group of
small epitheliotropic double stranded DNA viruses with more
than 200 types identified.1 HPV are arranged into classes
depending on their tissue tropism with mucosal HPV called
alpha and cutaneous types classified as beta, gamma, nu and
mu.2 There are 15 types that are thought to have a high- risk
oncogenic potential. High-risk types are linked with cervical
cancers, rarer anogenital cancers as well as oropharyngeal
squamous cell carcinoma (OPSCC). Oncogenic types 16, 18,
31, 33 and 35 are associated with OPSCC and more than
90% of HPV + OPSCC and 52–58% of cervical cancers are
induced by high-risk HPV16.3
Epidemiological studies show that OPSCC and especially
HPV + OPSCC incidence is increasing worldwide over the
last decades while the incidence of overall head and neck squa-
mous cancer (HNSCC) has declined in developed countries.4
Presently, the incidence of OSCC in the United States (U.S.)
is 6.2/100.000 for men and 1.4/100.000 for women.5 HPV is
thought to be the primary cause for this increasing incidence
of OPSCC and especially develops from the epithelium lining
the crypts of the palatine tonsils and base of tongue.6
In England the patients with diagnosis of tonsillar cancer
were 281 in 1997 and it increased to 703 in 2007; and in Sweden
the cases of tonsillar cancers are twice in number between 1970
and 2006 with HPV positivity increased from 23% to 79%.7,8
In 2005, Begum et al.9 detected HPV in 82% of patients with
tonsillar carcinoma. In recent studies prevalence of HPV in
OSCC is at least 60–70% and it is rising.10 Tural et al. demon-
strated the same increase of HPV positivity in 81 Turkish
patients with OPSCC. In this study HPV+ cases were 33%
in 1996–1999, 43% in 2000–2003, 55% in 2004–2007 and
70% in 2008–2011. They detected 86% HPV16, 12% HPV18
and 2% HPV33 from the samples.11
Cervical cancer is the third most common gynecological
cancer type in the world and approximately 500.000 women
are diagnosed as cervical cancer, yearly.12 HPV-DNA presence
was shown in 95% of the cervical cancer cases. HPV16 was
first isolated from cervical carcinoma in 1983 and since then
a significant effort has been dedicated to determine the onco-
genesis of HPV in the etiology of cervix cancer.13 With its
increasing incidence of HPV + OPSCC it is predicted that in
the year 2020 the number of HPV + OPSCC will be greater
than HPV related cervical cancers.102. Patients profile
HPV+ OPSCC has favorable outcomes and is seen in
younger people with lower exposure to tobacco and alcohol
comparing with HPV  OPSCC.14 HPV + OPSCC are mostly
seen in men with high socioeconomic status who are more
likely to be married.4,15 HPV positive cancers have a distinct
biology with lower T stage and higher nodal status with highAmerican Joint Committee on Cancer (AJCC) stage. However
these patients have surprisingly better prognosis with 60–80%
reduced risk of death comparing with HPV  OPSCC.16 This
prognostic advantage of HPV + OPSCC persists in multivari-
ate analyses with adjustment for age, tobacco exposure, per-
formance status and comorbidities.17
3. Risk factors
Sexual transmission of HPV to oropharyngeal sites, requires
mucosal orogenital skin to skin contact.18 HPV + OPSCC
patients have more exposure to sexual behaviors as compared
with HPV  OPSCC. Likewise sexual behaviors have an
important role as studies connected HPV + OPSCC with
increased lifetime number of oral and genital sexual partners,
younger age at the time of first sexual intercourse, infrequent
use of condoms and history of previous sexually transmitted
infection.19 Women with HPV + cervical cancer or carcinoma
insitu and their partners are at increased risk of HPV
+ OPSCC.20
Marijuana usage may also be another risk factor. Patients
with HPV + OPSCC have more marijuana exposure with
increasing intensity and duration comparing with
HPV  OPSCC.15 Beside this tobacco and alcohol exposure
does not act synergistically with HPV to increase the develop-
ment of HPV+ OPSCC. Also some studies reported that
French kiss (open mouth kissing) was found to be related with
the development of oral HPV infection.21 But on the other
hand some other studies have not found any relationship.22
4. Radiologic and histopathologic findings
Cystic metastatic cervical nodes have been strongly associated
with HPV + OPSCC that can cause erroneous diagnosis of
branchial cleft cyst.23 Finding HPV in a cervical metastasis
with unknown primary site is a strong indicator of oropharyn-
geal site for squamous cell cancers. Studies revealed distinct
radiological features of tumor and nodal characteristics
between HPV statuses. For example, HPV + OPSCC are
more likely to demonstrate exophytic well-defined borders,
whereas HPV  OPSCC tumors are likely to demonstrate
invasion of adjacent structures. In addition, well-defined cystic
metastases are suggested to be associated with HPV
positivity.24
At first studies HPV + OPSCC presented as poorly differ-
entiated with basaloid morphology.25 But recently with further
histopathological analysis it is described as well differentiated
because of the similarity in morphology to the reticulated
epithelium of the tonsillar cypts.26
5. Prognosis
It is not clear what could be responsible for the differences in
survival between HPV+ and HPV patients. One difference
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pressor protein retinoblastoma (pRB) and tumor suppressor
protein 53 (p53) pathways in HPV + OPSCC and the loss in
HPV  OPSCC.27 HPV + OPSCC patients have a better
prognosis and have more response to treatment comparing
with HPV  OPSCC patients.14 Gillison et al.25 reported that
patients with HPV + OPSCC had a significantly improved
response to induction chemotherapy (82% vs. 55%). These
patients have better rates of overall and progression free sur-
vival.14 HPV + OPSCC has also been shown to respond better
to radiation therapy independent from the radiation regi-
men.28 Also invitro HPV positive cell-line experiments showed
increased apoptosis and decreased survival with the radiation
exposure consisted with radiation sensitivity.29
Also p16 immunochemistry which is the surrogate marker
for HPV positivity, is the most important prognostic variable
comparing with traditional prognostic factors in OPSCC for
cancer specific survival and recurrence free survival. Oguejio-
for et al.1 presented 217 patients with OPSCC and 61% of
these were p16 tumor that occurred in non smoker, younger
patients (56 vs. 64), with low alcohol use, low T stage, high
N stage, high AJCC stage and poor differentiation. In this
study they showed that the prognostic strength of p16 sur-
passes the traditional prognostic markers such as TNM classi-
fication also suggesting that the current prognostic
classifications has no benefit in HPV + OPSCC.
In HPV + OPSCC the presence of clinical metastasis did
not appear to be associated to primary tumor size. Recent
studies results support treating both necks in all stages of
HPV + base of tongue SCC. HPV + tonsillar complex can-
cers had a low rate of bilateral disease suggesting that unilat-
eral treatment neck may be adequate.24
While loco-regional control is significantly higher in HPV
+ OPSCC, distant metastasis has not been always improved.17
In HPV + OPSCC mutiple organ metastasis could occur
including the skin, intra-abdominal lymph nodes and brain
much more later comparing with HPV  OPSCC.30 Also
recent studies showed possible relationship between viral onco-
gene expression, viral load and prognosis.66. Oncogenesis induced by HPV infection
HPV+ tumors are induced by the viral infection of HPV.
Oral HPV infection is mostly cleared and does not lead to
malignant process.31 Gillison et al.32 showed the overall preva-
lence of oral HPV infection was 7% among more than 5000
women and men in U.S. Infection risks correlate with the rise
in the number of sexual partners. Oral HPV prevalence was
found to be higher in women at 17% with a cervical HPV
infection in accordance with HPV type between the cervical
and oral sites.33
In some of these even in healthy patients HPV infection
persists and this can result in the cancer formation. Immune
escape is one of the main processes that causes this HPV infec-
tion persistence, finally forming the cellular malign transfor-
mation. The main viral oncoproteins mediating the immune
escape are E5, E6, E7.16 Generally in patients where HPV per-
sists there are lower responses to early antigens comparing to
late antigens. Early antigens only emerged once HPV is
already invasive. Pathways of transformation from infection
to cancer have been well documented including the viral onco-protein E6 which declines the quality of p53 and viral oncopro-
tein E7 that induced the down regulation of pRb. E7 also
increases the p16 expression that can be used as a surrogate
marker to detect the oncogenic HPV action.4 Inactivation of
retinoblastoma by the HPV oncogen E7 triggers this upregula-
tion of p16 which is usually lost in HPV  OPSCC.1
HPV  OPSCC tumors have more mutations comparing
with HPV+ OPSCC independent from smoking status. Stran-
sky et al.34 report that the mutation rate of HPV + tumors is
half the rate of HPV–tumors and higher mutation rate predis-
poses them to reoccurrence and resistance to therapy. Detailed
knowledge about oncogenesis is far beyond this review.
6.1. Diagnosis of HPV oncogenesis
Although the risk factors and the increasing incidence of HPV
+ OPSCC are well known there is no standard screening test
available for the detection of early HPV lesions in orophar-
ynx.2 Because it is the most important prognostic factor in
OPSCC; HPV status detection has been included into National
Comprehensive Cancer Network guidelines as a clinical stan-
dard care.5
For the diagnosis of HPV+ OPSCC, diagnostic methods
detect; DNA, RNA or surrogate markers of HPV infection.
There is a discussion about the best way to identify HPV
+ OPSSC. Currently, there is no standard testing method
for HPV + OPSCC assays. In situ hybridization (ISH) for
HPV DNA and polymerase chain reaction (PCR) for HPV
DNA and HPV mRNA, and immunohistochemistry (IHC)
for a surrogate marker p16 are applied alone or in combina-
tion.6 This immunohistochemical p16 expression, was accepted
positive when there was a strong and diffuse brown staining of
the nucleus and cytoplasm in more than 70% of the tumor
specimens.35
Although some studies evaluate the mRNA detection by
real time PCR as the gold standard procedure; there are some
disadvantages of this technique. These are the need for fresh
samples and the uncommon usage of this procedure in a rou-
tine pathology laboratory.
There are patients who are p16 positive but HPV DNA
PCR and/or IHS negative.16 The use of p16 alone could cause
an overestimated results of HPV+ OPSCC. Therefore for for-
malin fixed paraffin embedded samples DNA detection with a
IHC for p16 for confirmation may be an adequate diagnostic
method.6
7. New treatment strategies
Recently studies focus on reduction of treatment-related toxi-
city. These include dose reduction of radiotherapy, using
cetuximab instead of cisplatin for chemoradiation, transoral
robotic surgery (TORS), and immunotherapeutic strategies.14
For all these strategies, the main goal is to improve functional
quality of life.36
7.1. Immunotherapeutic strategies
In most of the patients, local HPV infection can finally be
cleared through an arrangement of specific T cell mediated
immunity.16 HPV + OPSCC expresses viral oncoproteins that
have immunogenic potential. Most important ones are
130 O.T. Selcukoncoproteins E6 and E7. Heusinkveld et al. showed the pres-
ence of HPV16 specific T cell immunity in HPV16 + HNSCC
Albers et al. founded E7 specific circulating T lymphocytes in
patients with HPV+ OPSCC. These studies reinforced a role
for immune surveillance in patients.37,38
The increasing immunological knowledge of HPV
+HNSCC produces great interest for new and HPV specific
treatments. Vaccines are intended to stimulate an anti tumor
immune response. In the study about vaccination against
HPV-16 oncoproteins E6 and E7 for vulvar intraepithelial neo-
plasia showed complete response in some of the patients and
clinical response in most of the patients.39 Recently Voskens
et al.40 published their study about HPV-16 immunity by Tro-
jan vaccines in patients with recurrent or metastatic head and
neck carcinoma.
There are also ongoing studies about the therapies of HPV
+ OPSSC and HPV+ cervical cancer with immunomodula-
tors (toll like receptors), cytokines (IL-2, IL-12, GM-CSF
and IFN-alpha), non-viral HPV peptide and protein vaccines,
DNA vaccines, tumor cellular vaccine, dendritic cell vaccines,
bacterial vectors (Listeria Monocytogenes), T cell therapy and
targeted immunotherapy by live viral vector.16
A modified vaccinia virus TG4001 was designed to express
HPV-16 oncoproteins E6 and E7 and in a recent study is used
in cervical cancer patients with successful results.41 Nowadays
a phase II trial is performedthat combines the TG400 and
chemoradiotherapy in patients with HPV + OPSCC.16
Recently studies about immune escape showed an immune
resistance mechanism which is mediated through programed
death 1 protein (PD-1) and ligand of this receptor PD-L1.
Usage of PD-L1 and PD-1 antibody in patients with advanced
cancer are safely and actively demonstrated, and there are
studies ongoing about this treatment approach for HPV
+HNSCC.14 Further studies will end up targeted, effective
treatments with reduced toxicity.
7.2. Dose reduction of radiotherapy
The biologic basis for better outcome seen in HPV + OPSCC
patients is unknown. There is conspiracy about the sensitivity
to radiation. HPV + OPSCC patients are younger and health-
ier with better prognosis comparing with those with
HPV  OPSCC so reducing the long term complications of
radiotherapy such as swallowing difficulties, salivary gland
dysfunction, speech problems, dental dysfunction while still
achieving oncologic cure gains much importance. It is clear
that giving less dose of standard dose of radiotherapy (70 Gy
down to 54 Gy) results in less toxicity.42 Dose reduction of
radiotherapy also has potential benefits like decrease in the
cost of the treatment and reduction in the time of starting work
and unemployment in these young patients.43
Beside these benefits also any trial to decrease the intensity
of radiotherapy includes the risk of worsening outcomes. Also
there are psychological difficulties as demonstrated by
Brotherston et al.44 in their study about the patient preferences
for oropharyngeal cancer treatment de-escalation. In this study
almost 70% of patients were indisposed to risk a 5% decrease
in survival by the change of the treatment from chemoradia-
tion to radiation alone. Several studies showed that the
patients who have T4 or N3 disease are at risk of dose
reduction.427.3. Monoclonal antibody therapy
Cisplatin is gold standard agent for chemoradiation for
HNSCC but platinum based agents have systemic complica-
tions as renal, otologic, hematologic, neurologic and gastroin-
testinal toxicities. For HNSCC the approved monoclonal
antibody therapy is cetuximab. Replacement of cisplatin with
less toxic cetuximab is another way to reduce toxicity. Kabo-
lizadeh et al. showed that radiation plus cetuximab combina-
tion is beneficial over radiation alone, especially in young
males without tobacco history with OPSSCC.45 At the Univer-
sity of Pittsburgh a phase I clinical trial (UPCI 12-084) com-
bining concurrent ipilimumab (the monoclonal antibody
specific to CTLA-4) plus cetuximab with radiation had just
started.16
There is also discussion about cetuximab theraphy. There
are first results of studies going on that a cetuximab-based
radiotherapy is comparing cisplatin regimen with better qual-
ity of life without significant difference in locoregional control
or survival.14 But on the other hand some data suggest that
this combination may not be the preferred therapy.6
7.4. The need for adjuvant chemotherapy
Sinha et al.46 showed the need for reconsideration of
chemotherapy added to adjuvant radiotherapy for p16-
positive oropharyngeal cancer due to their studies resulted as
the adjuvant chemoradiotherapy was not related with superior
disease free survival comparing to radiotheraphy alone.
7.5. Transoral robotic surgery (TORS)
TORS is a new, less invasive, oncologically safe procedure that
reduces the morbidity for HPV+ OPSCC comparing with
open surgery with lip split and mandible split that have func-
tional impairments.47 The usage of TORS started in animal
models in 2003 and it was first used in a patient in 2005 for
a vallecula cyst and the first case of base of tongue tumor exci-
sion published in 2006.48,49 Since then many studies published
about the usage of TORS with functional outcomes in
OPSCC.50 The FDA approved TORS for T1-T2 OPSCC. As
known the patients with HPV+ OPSCC have early T grades
so are considered good candidates for this procedure.47 Also
TORS is an alternative for chemoradiation for these patients.
One of the main criticisms against using the robotic surgery
is the cost of the operation. But when we consider of the avail-
ability of ‘Da Vinci’ robotic operations for 4 departments; uro-
logical, gynaecological, abdominal and otolaryngological the
cost is diminished. Also this less invasive procedure provides
less hospitalization with early recovery. There are studies going
on to determine the role of TORS in the treatment algorithm.4
8. Prevention by prophylactic vaccination
Since 2006, there are two types of recombinant HPV vaccines
available named as bivalent and quadrivalent vaccine that are
approved by Food and Drug Administration (FDA) against
HPV types 6, 11, 16, 18. The preventative HPV vaccination
programs represent a positive step in HPV associated cancer
prevention. World Health Organization (WHO), recommends
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of sexual activity for prevention of cervical cancers. By 2010,
33 developed countries included these vaccines into their
national vaccination program for the target population mostly
for preventing the cervical cancer.12 Australia is the first coun-
try that started the national HPV vaccination program in 2007
for all 12–17 years old school girls. They extended their pro-
gram to all 12–13 years old school girls and boys in 2013.51
In United Kingdom vaccination of 12–13 year old school girls
for preventing cervical cancers began in 2008 for HPV16 and
HPV18. In Sweden; since 2010 HPV vaccinations have been
recommended to all girls who were born in 1999 and later
and since 2012; all 10–12 years old girls are vaccinated in
schools.33 However most of the developing and underdevel-
oped countries where cervical cancer incidence is higher do
not have a national HPV vaccination programs.12
Although these HPV vaccines are mostly used for the pre-
vention of cervical cancer with the prevention rates up to
70%, they may also have prophylactic potential to prevent
the processing of 95% of HPV + OPSCC.2 High efficacy in
preventing the cervical cancers have been demonstrated but
there are no specific data for preventing HPV + OPSCC. In
U.S.; Center for Disease Control and Prevention and the
American Academy of Pediatrics have recommendations of
vaccination of three intramuscular doses in 6 months for
men and women between the ages of 11 and 26. Beside these
recommendations currently only 35% of population in U.S.
completes the three injection series.42 Although Turkish Soci-
ety of Gynecological Oncology recommends the HPV vaccina-
tion we do not have a national HPV vaccination program or
policy in Turkey.52 Although HPV vaccines have the potential
to reduce the incidence of HPV + OPSCC, it will take decades
for these vaccination program to affect the cancer rates.
8.1. Prevention by education and social awareness
The protection methods, condoms and barrier protections dur-
ing the oral sexual intercourse must be used as HPV
+ OPSCC is a sexually transmitted disease. Social awareness
and education about the role of the HPV in the development
of OPSCC and the protection methods must be achieved.
Recently in 2014 a campaign created in Turkey with the
support of the Turkish Medical Oncology Association, Turk-
ish Otorhinolaryngology and Head and Neck Surgery Associ-
ation, Turkish Association of Radiation Oncology and
Turkish Ministry of Health Public Health Institute Depart-
ment of Cancer called ‘Head and Neck Cancer Awareness
Week’ was carried out to the raise the awareness of society
about head and neck cancers and the role of HPV infection
as a risk factor in development of these cancers.53
9. Conclusion
The prevalence of HPV + OPSCC is rising globally and HPV
positivity has better prognosis, overall, recurrence free and dis-
ease specific survival regardless of treatment regimen. Cur-
rently, OPSCC patients are treated regardless of HPV status,
the detection of HPV status for these patients is mostly for par-
ticipation in the clinical studies.
More controlled prospective clinical studies are required
globally to define the de-intensification including; TORS andnew targeted therapeutic strategies for HPV+ OPSCC also
standardization of the diagnostic test for HPV status is a
necessity because caution needs to be applied so as not to
assume a risk of the better prognosis of patients with HPV
+ OPSCC.
Also we must plan a large, multicentered HPV + OPSCC
prevalence study to determine the geographical and sociocul-
tural variations and a national HPV vaccination program must
be initiated for girls and boys to reduce future cancer rates in
Turkey.
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